Patents Examined by Lynn A. Bristol
  • Binding molecules specific for HER3 and uses thereof
    Patent number: 10040857
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 7, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Synergistic combination of immunologic inhibitors for the treatment of cancer
    Patent number: 10034939
    Abstract: In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: July 31, 2018
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Stefani Spranger, Michael Leung
  • Caninized murine antibodies to human PD-1
    Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
    Patent number: 10023892
    Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(?2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds Fc?RIIA or Fc?RIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by Fc?R is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: July 17, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Che Ma
  • Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
    Patent number: 10011659
    Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: July 3, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Maicol Mancini, Nadège Gaborit
  • Anti-HER2 glycoantibodies and uses thereof
    Patent number: 10005847
    Abstract: The present disclosure relates to a novel class of anti-HER2 monoclonal antibodies comprising a homogeneous population of anti-HER2 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-HER2 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: June 26, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Antibody variants having modifications in the constant region
    Patent number: 10000570
    Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: June 19, 2018
    Assignee: Genmab A/S
    Inventors: Aran Frank Labrijn, Stefan Loverix, Paul Parren, Jan Van De Winkel, Janine Schuurman, Ignace Lasters
  • Anti-CD33 antibodies and methods for treatment of acute myeloid leukemia using the same
    Patent number: 10000566
    Abstract: The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 19, 2018
    Assignee: IMMUNOGEN, INC.
    Inventors: Mary G. Hoffee, Daniel Tavares, Robert J. Lutz
  • Humanized antibodies to cluster of differentiation 3 (CD3)
    Patent number: 10000567
    Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: June 19, 2018
    Assignee: Therapix Biosciences Ltd.
    Inventors: Ronald Ellis, Michael Tal, Sarit Samira, Nurit Rachamim, Timothy David Jones, Francis Joseph Carr, Shahar Dotan
  • Compositions and methods for treatment and detection of cancers
    Patent number: 9982041
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, lung, breast, mouse, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervix, ovary, and/or prostate cancer.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 29, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Tsui-Ling Hsu, Yi-Wei Lou, Chih-Wei Lin, Shih-Chi Yeh, Chung-Yi Wu, Han-Chung Wu
  • Compositions and methods for treatment and detection of cancers
    Patent number: 9975965
    Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.
    Type: Grant
    Filed: January 30, 2016
    Date of Patent: May 22, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Tsui-Ling Hsu, Yi-Wei Lou, Chih-Wei Lin, Shih-Chi Yeh, Chung-Yi Wu, Han-Chung Wu
  • Method for eliciting an immune response to an immunogen
    Patent number: 9962438
    Abstract: The invention relates to methods for eliciting an immune response to an immunogen, and in particular, to such methods using polymersomes as carriers for the immunogen.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: May 8, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Madhavan Nallani, Fabien Decaillot, Zhikang Fu, Xingfang Su
  • Antibody-based affinity reagents for binding paclitaxel
    Patent number: 9964551
    Abstract: Optimized affinity reagent compositions for binding paclitaxel, such as antibodies, antibody fragments, and antibody derivatives, related methods of use, and related kits, are provided herein. Affinity reagents that comprise one or more complementary determining regions (CDRs) optimized from anti-paclitaxel antibodies antibody 8A10 and 3C6 are specifically provided. The disclosed affinity reagents are useful for binding and detecting paclitaxel in a sample, such as for determining or optimizing future doses of paclitaxel in a subject that was previously administered with paclitaxel.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: May 8, 2018
    Assignee: AUTOTELIC, LLC
    Inventors: Vuong Trieu, Chulho Park
  • Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor
    Patent number: 9943596
    Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: April 17, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jimin Lee, Bo Gyou Kim, Seungja Oh, Kyung Ah Kim, Powei Lin, Saet Byoul Lee
  • Anti-PD-1 antibodies and their uses
    Patent number: 9914783
    Abstract: The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: March 13, 2018
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Daniel E. H. Afar, Fiona A. Harding, Josue Samayoa
  • Antibody molecules to LAG-3 and uses thereof
    Patent number: 9908936
    Abstract: Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious disorders.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 6, 2018
    Assignees: Novartis AG, Immutep S.A.S.
    Inventors: Frédéric Triebel, Chrystelle Brignone, Walter A. Blattler, Jennifer Marie Mataraza, Catherine Anne Sabatos-Peyton, Hwai Wen Chang, Gerhard Johann Frey
  • Sequence asymmetric modified IgG4 bispecific antibodies
    Patent number: 9902768
    Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterized in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 27, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Paul Humphreys, Shirley Jane Peters
  • Bispecific heterodimeric diabodies and uses thereof
    Patent number: 9884921
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Chad Michael May, Adam Reid Root, William A. Brady, Lioudmila Gennadievna Tchistiakova, Lidia Mosyak, Laird Bloom, Paul A. Moore, Leslie S. Johnson
  • Antibody molecules to TIM-3 and uses thereof
    Patent number: 9884913
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: February 6, 2018
    Assignees: Novartis AG, DANA-FARBER CANCER INSITITUTE, INC., Children's Medical Center Corporation
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • CTLA-4 variants
    Patent number: 9884902
    Abstract: Variants of cytotoxic T-lymphocyte antigen 4 (CTLA-4) with high affinity, potency and stability. Formulations of CTLA-4 variants at high concentration for subcutaneous or intravenous administration, e.g. at monthly or less frequent dosage intervals. Use of CTLA-4 variants for treating rheumatoid arthritis and other inflammatory disorders. Fusion of CTLA-4 with IgG Fc having improved stability and longer in vivo half-life.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: February 6, 2018
    Assignee: MedImmune Limited
    Inventors: Ralph Minter, Julie Douthwaite, Jacques Moisan, Michael Bowen, Steven Rust, Cyril Privezentzev